Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis

Immunotherapy

Volumn 5, Issue 12, 2013, Pages 1313-1322

  Guan, Qingdong ^a   Burtnick, Helen A ^a   Qing, Gefei ^a   Weiss, Carolyn R ^a   Ma, Allan G ^a   Ma, Yanbing ^b   Warrington, Richard J ^a   Peng, Zhikang ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Crohns disease; IL 23; inflammatory bowel disease; TNBS induced colitis; vaccine

Indexed keywords

HEPATITIS B CORE ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 P19 VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; COLITIS; COLON; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; MICE; MICE, INBRED BALB C; PEPTIDES; SPLEEN; TRINITROBENZENESULFONIC ACID; VACCINATION; VACCINES, SUBUNIT; WEIGHT LOSS;

EID: 84889601193     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.141     Document Type: Article

References (35)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010)
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 474(7351), 307-317 (2011)
3. Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 22(4), 361-364 (2006)
4. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140(6), 1756-1767 (2011)
5. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu. Rev. Med. 58, 433-444 (2007) (Pubitemid 46706525)
6. Neurath MF. IL23: a master regulator in Crohn disease. Nat. Med. 13(1), 26-28 (2007)
7. Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112(4), 1169-1178 (1997) (Pubitemid 27157528)
8. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182(5), 1281-1290 (1995)
9. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL12p40 to form a cytokine, IL23, with biological activities similar as well as distinct from IL12. Immunity 13(5), 715-725 (2000)
10. Yen D, Cheung J, Scheerens H et al. IL23 is essential for T cell-mediated colitis and promotes inflammation via IL17 and IL6. J. Clin. Invest. 116(5), 1310-1316 (2006)
11. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. 5(3), 197-209 (2006) (Pubitemid 43336033)
12. Hue S, Ahern P, Buonocore S et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203(11), 2473-2483 (2006) (Pubitemid 44664617)
13. Kullberg MC, Jankovic D, Feng CG et al. IL23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203(11), 2485-2494 (2006) (Pubitemid 44664618)
14. Elson CO, Cong Y, Weaver CT et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132(7), 2359-2370 (2007) (Pubitemid 46890867)
15. Ahern PP, Schiering C, Buonocore S et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33(2), 279-288 (2010)
16. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804), 1461-1463 (2006) (Pubitemid 44871953)
17. Baert F, De Vos M, Louis E, Vermeire S. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70(2), 163-170 (2007) (Pubitemid 47066267)
18. Guan Q, Ma Y, Aboud L et al. Targeting IL23 by employing a p40 peptide-based vaccine ameliorates murine allergic skin and airway inflammation. Clin. Exp. Allergy 42(9), 1397-1405 (2012)
19. Uyttenhove C, Sommereyns C, Theate I, Michiels T, Van Snick J. Anti-IL17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 1110, 330-336 (2007) (Pubitemid 350043022)
20. Delavallee L, Semerano L, Assier E et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res. Ther. 11(6), R195 (2009)
21. Spohn G, Guler R, Johansen P et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178(11), 7450-7457 (2007) (Pubitemid 46847473)
22. Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38(3), 877-887 (2008)
23. Guan Q, Ma Y, Hillman CL et al. Targeting IL12/IL23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol. Med. 17(7-8), 646-656 (2011)
24. Ma Y, Hayglass KT, Becker AB et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am. J. Respir. Crit. Care Med. 176(5), 439-445 (2007) (Pubitemid 47358097)
25. Ma Y, Guan Q, Bai A et al. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm. Bowel Dis. 16, 1040-1050 (2010)
26. Guan Q, Ma Y, Hillman CL et al. Development of recombinant vaccines against IL12/IL23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 27(50), 7096-7104 (2009)
27. Beyer BM, Ingram R, Ramanathan L et al. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. J. Mol. Biol. 382(4), 942-955 (2008)
28. Moriyama I, Ishihara S, Rumi MA et al. Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab. Invest. 88(6), 652-663 (2008) (Pubitemid 351733283)
29. Fichtner-Feigl S, Fuss IJ, Young CA et al. Induction of IL13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J. Immunol. 178(9), 5859-5870 (2007) (Pubitemid 46674383)
30. Dalum I, Butler DM, Jensen MR et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 17(7), 666-669 (1999) (Pubitemid 29316144)
31. Zuany-Amorim C, Manlius C, Dalum I et al. Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int. Arch. Allergy Immunol. 133(2), 154-163 (2004) (Pubitemid 38314647)
32. Delavallee L, Assier E, Denys A et al. Vaccination with cytokines in autoimmune diseases. Ann. Med. 40(5), 343-351 (2008) (Pubitemid 351882892)
33. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72(11), 6519-6527 (2004) (Pubitemid 39425433)
34. Becker C, Dornhoff H, Neufert C et al. Cutting edge: IL23 cross-regulates IL12 production in T cell-dependent experimental colitis. J. Immunol. 177(5), 2760-2764 (2006) (Pubitemid 44277789)
35. Ratsimandresy RA, Duvallet E, Assier E et al. Active immunization against IL23p19 improves experimental arthritis. Vaccine 29(50), 9329-9336 (2011)